IL135528A0 - Papilloma virus capsomere vaccine formulations and methods of use - Google Patents

Papilloma virus capsomere vaccine formulations and methods of use

Info

Publication number
IL135528A0
IL135528A0 IL13552898A IL13552898A IL135528A0 IL 135528 A0 IL135528 A0 IL 135528A0 IL 13552898 A IL13552898 A IL 13552898A IL 13552898 A IL13552898 A IL 13552898A IL 135528 A0 IL135528 A0 IL 135528A0
Authority
IL
Israel
Prior art keywords
methods
vaccine formulations
papilloma virus
capsomere vaccine
virus capsomere
Prior art date
Application number
IL13552898A
Other languages
English (en)
Original Assignee
Univ Loyola Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Loyola Chicago filed Critical Univ Loyola Chicago
Publication of IL135528A0 publication Critical patent/IL135528A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13552898A 1997-10-06 1998-10-06 Papilloma virus capsomere vaccine formulations and methods of use IL135528A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/944,368 US6228368B1 (en) 1997-10-06 1997-10-06 Papilloma virus capsomere formulations and method of use
PCT/US1998/020965 WO1999018220A1 (en) 1997-10-06 1998-10-06 Papilloma virus capsomere vaccine formulations and methods of use

Publications (1)

Publication Number Publication Date
IL135528A0 true IL135528A0 (en) 2001-05-20

Family

ID=25481268

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13552898A IL135528A0 (en) 1997-10-06 1998-10-06 Papilloma virus capsomere vaccine formulations and methods of use
IL135528A IL135528A (en) 1997-10-06 2000-04-06 Vaccine vaccine from capsule virus and methods of use
IL190554A IL190554A0 (en) 1997-10-06 2008-04-01 Papilloma virus capsomere vaccine formulations and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL135528A IL135528A (en) 1997-10-06 2000-04-06 Vaccine vaccine from capsule virus and methods of use
IL190554A IL190554A0 (en) 1997-10-06 2008-04-01 Papilloma virus capsomere vaccine formulations and methods of use

Country Status (21)

Country Link
US (4) US6228368B1 (de)
EP (2) EP1690941B1 (de)
JP (3) JP4520034B2 (de)
KR (1) KR20010030969A (de)
AT (2) ATE349536T1 (de)
AU (1) AU9684698A (de)
BR (1) BR9814606A (de)
CA (1) CA2305382A1 (de)
CY (1) CY1105963T1 (de)
CZ (1) CZ302351B6 (de)
DE (2) DE69836753T2 (de)
DK (1) DK1021547T3 (de)
ES (2) ES2337492T3 (de)
HU (1) HU225893B1 (de)
IL (3) IL135528A0 (de)
NO (2) NO328128B1 (de)
NZ (1) NZ503830A (de)
PL (1) PL195332B1 (de)
PT (1) PT1021547E (de)
TR (1) TR200001842T2 (de)
WO (1) WO1999018220A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000092I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) * 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
FI107932B (fi) * 1999-02-16 2001-10-31 Mikael Paronen Polymeerikalvo ja menetelmä sen valmistamiseksi
US6551597B1 (en) * 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
EP1212358B1 (de) * 1999-08-25 2004-12-15 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
CA2875298A1 (en) * 1999-12-09 2001-06-14 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
DE10059630A1 (de) * 2000-12-01 2002-06-06 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von durch humanen Papillomavirus-Typ 18-hervorgerufenem Tumor
AU2002367977B2 (en) 2001-08-13 2008-06-19 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
AU2002326093A1 (en) * 2001-08-31 2003-03-10 University Of Cape Town Papillomavirus proteins and pharmaceutical compositions
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
SI1506222T1 (sl) † 2002-05-17 2009-10-31 Universty Of Cape Town Himerni L1-proteini humanega papilomavirusa 16, ki obsegajo L2-peptid, delci, podobni virusu, pripravljeni iz njih, in postopek za pripravo delcev
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
ES2431963T3 (es) 2002-07-05 2013-11-28 Folia Biotech Inc. Partícula viral adyuvante
SE0202897D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method and kit for quantitative and qualitative determination of human papillomavirus
SE0202896D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method for estimating the risk of carcinoma development
US7763259B2 (en) * 2003-01-10 2010-07-27 The Regents Of The University Of Colorado Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
US7172773B2 (en) * 2004-04-26 2007-02-06 Renew Life Inc. Food supplement formulation
ATE474596T1 (de) * 2004-09-10 2010-08-15 Asahi Glass Co Ltd Impfstoff gegen humanes papillomavirus zur oralen verabreichung
EP1819835B1 (de) 2004-12-08 2010-08-04 Gen-Probe Incorporated Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
WO2008134935A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
US9428555B2 (en) * 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
DK2154149T3 (da) * 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
US8507811B2 (en) * 2009-02-02 2013-08-13 Apple Inc. Touch sensor panels with reduced static capacitance
EP2377879A1 (de) * 2010-04-14 2011-10-19 Deutsches Krebsforschungszentrum N-terminale HPV E7-Fusionsproteine
WO2015196112A1 (en) 2014-06-19 2015-12-23 The Regents Of The University Of Colorado, A Body Corporate Human papilloma virus constructs
WO2016026919A1 (en) * 2014-08-20 2016-02-25 Ruprecht-Karls-Universität Heidelberg Vaccines and manufacturing methods for treatment and prevention of disease
WO2021013067A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
US11382700B2 (en) 2020-05-08 2022-07-12 Globus Medical Inc. Extended reality headset tool tracking and control
US11510750B2 (en) 2020-05-08 2022-11-29 Globus Medical, Inc. Leveraging two-dimensional digital imaging and communication in medicine imagery in three-dimensional extended reality applications

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194839T3 (es) 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
EP1835029A1 (de) 1992-06-25 2007-09-19 Georgetown University Impfstoffe gegen den Papillomavirus
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
ATE492289T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
DE122007000092I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
DE4435907C2 (de) 1994-10-07 1997-07-24 Lutz Prof Dr Gissmann Papillomavirusähnliche Partikel und deren Anwendung
JP3413020B2 (ja) * 1996-07-17 2003-06-03 株式会社東芝 半導体装置の製造方法
DE19712541C1 (de) 1997-03-25 1998-11-05 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
CA2295316C (en) * 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
WO1999010557A1 (fr) 1997-08-26 1999-03-04 Nsk Ltd. Procede de production d'un palier a roulement
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Also Published As

Publication number Publication date
IL135528A (en) 2008-06-05
NO20001768L (no) 2000-06-02
US7754430B2 (en) 2010-07-13
DE69836753D1 (de) 2007-02-08
NZ503830A (en) 2002-09-27
IL190554A0 (en) 2008-11-03
EP1021547A1 (de) 2000-07-26
NO20091761L (no) 2000-06-02
CZ302351B6 (cs) 2011-03-30
US7371391B2 (en) 2008-05-13
ES2337492T3 (es) 2010-04-26
JP5296665B2 (ja) 2013-09-25
JP2010095530A (ja) 2010-04-30
US20090028894A1 (en) 2009-01-29
EP1690941B1 (de) 2009-11-25
ATE449852T1 (de) 2009-12-15
CY1105963T1 (el) 2011-04-06
US6228368B1 (en) 2001-05-08
EP1690941A1 (de) 2006-08-16
US20050031636A1 (en) 2005-02-10
ES2280104T3 (es) 2007-09-01
CA2305382A1 (en) 1999-04-15
AU9684698A (en) 1999-04-27
PL195332B1 (pl) 2007-09-28
EP1021547B1 (de) 2006-12-27
JP2001519161A (ja) 2001-10-23
ATE349536T1 (de) 2007-01-15
JP4520034B2 (ja) 2010-08-04
WO1999018220A1 (en) 1999-04-15
JP2013147507A (ja) 2013-08-01
TR200001842T2 (tr) 2000-12-21
CZ20001244A3 (en) 2001-05-16
HUP0004360A2 (en) 2001-03-28
KR20010030969A (ko) 2001-04-16
HU225893B1 (en) 2007-12-28
DE69841342D1 (de) 2010-01-07
US20060198853A1 (en) 2006-09-07
HUP0004360A3 (en) 2003-03-28
NO20001768D0 (no) 2000-04-06
PL339735A1 (en) 2001-01-02
PT1021547E (pt) 2007-02-28
BR9814606A (pt) 2002-01-02
DK1021547T3 (da) 2007-04-23
NO328128B1 (no) 2009-12-14
DE69836753T2 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
IL190554A0 (en) Papilloma virus capsomere vaccine formulations and methods of use
CA2229955A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
PL317234A1 (en) Vaccines against papilloma virus
EP1820853A3 (de) Rekombinante Influenzaviren für Impfstoffe und Gentherapie
WO1999033868A3 (en) Human papillomavirus vaccine
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
PH31441A (en) 5.Substituted derivatives of mycophenolic acid.
HUP0004327A1 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
AU8762991A (en) Human papilloma viral protein expression for use in vaccine compositions
EP1891968A3 (de) Rotavirusimpfstoff-Formulierungen
AU8684991A (en) Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives
IL131212A0 (en) Recombinant virus and live-virus vaccines
HUP9904171A3 (en) Immunogenic peptides of foot-and-mouth disease viruses
CA2275259A1 (en) Formulations of recombinant papillomavirus vaccines
AU2003200653A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
HK1032974A (en) Human papillomavirus vaccine
AU6051396A (en) Measles virus recombinant poxvirus vaccine
GB9503395D0 (en) Viral,preparations,immunogens,and vaccines
IT1270184B (it) Uso di proteine da schock termico per il trattamento di malattie virali di interesse veterinario

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted
KB Patent renewed